Proprietary Formulations

On the forefront of both science and business strategy, OneQor has pioneered life-changing research to establish best-in-class formulations for precision-made applications.

Cannabinoid researchers working alongside pharmaceutical professionals.

Experience the OneQor difference.

OneQor’s research and development process is led by Dr. Joseph Fortunak, a Professor of Chemistry and Pharmaceutical Sciences at Howard University in Washington D.C. Before joining OneQor, Professor Fortunak spent 21 years as an innovator in the pharmaceutical industry, where he contributed to the launch of 15 drugs and over 25 generic products, totaling sales in excess of $100 billion. In addition, Dr. Anthony K. Wutoh, Provost and Chief Academic Officer, has committed the resources of The Howard University Interdisciplinary Research Building (HUIRB) for OneQor's ongoing R&D efforts.

Partnered for a purpose.

In addition to groundbreaking R&D work, OneQor has pioneered life-changing research — using a biomimicry-based focused — to reduce back pain, foot pain, HIV-related pain, anti-aging, acne, anxiety, hair health, and more. All part of the OneQor mission to help everybody truly Start Living. In order to live well, pain needs to be managed in a healthy, effective, and non-addictive way. To make this happen, we've established partnerships with top-tier operators and international generic pharmaceutical providers.

Innovation backed by expert opinions.

OneQor’s advisory board is headed by the University of Maryland’s Robert Gallo, MD, a distinguished recipient of the Albert E. Lasker Award in Medical Research, and co-discoverer of the HIV virus as the cause of AIDS. Dr. Gallo is Director and Co-Founder of the Institute of Human Virology (IHV) at the University of Maryland School of Medicine. The IHV combines the disciplines of basic science, epidemiology, and clinical research in a concerted effort to speed discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders. Dr. Gallo is joined on the OneQor advisory board by Terry Lierman, Chairman of the IHV. Mr. Lierman manages world-renowned work from experts in the field of human virology.

Science team

Chief Science Officer

Dr. Joseph Fortunak

Joseph Fortunak is a Professor of Chemistry and Pharmaceutical Sciences at Howard University in Washington D.C. Dr. Fortunak also holds honorary appointments at several other institutions in the US and overseas. He previously spent 21 years as an innovator in the pharmaceutical industry, where he contributed to the launch of 15 new drugs and 25+ new generic products whose total sales exceeded $100 billion.

Read More

His research includes Green Chemistry; novel, leap-frogging technologies; and pharmacokinetic enhancers to reduce the cost/toxicity of medicines and promote sustainable, global access. Dr. Fortunak works with producers, government agencies, and non-Governmental Organizations in the US, India, China, and Africa including the US FDA, USAID, WHO, UNAIDS, UNITAID, UNIDO, USP, and the Global Fund for AIDS, TB, and Malaria. This work is represented in over 22 million people taking HIV medicines in low- and middle-income countries (LMICs). These efforts reduced the cost of treating people with Hepatitis C and AIDS in LMICs by $1.85 billion in 2013- 2017. He has received numerous awards including the American Chemical Society “Heroes of Chemistry”, and a US FDA Honor Award for Excellence and Innovation in Africa. Dr. Fortunak has over 100 publications and 35+ patents and patent applications.


Dr. Nick Sisti

Dr. Sisti received his Ph.D. in Organic Chemistry from the State University of New York at Stony Brook and his J.D. from Suffolk University and was both a NATO and Chateaubriand scholar studying at the prestigious Institute for Natural Products Research in Gif-sur Yvette France (CNRS-ICSN)  Dr. Sisti is admitted to practice in Connecticut and the United States Patent and Trademark Office.

Read More

Dr. Sisti has over 10 years experience as an innovator in the pharmaceutical industry where he was the sole or co-inventor on 16 issued United States Patents focusing on the anticancer drugs Taxol (Paclitaxel), Taxotere and Topotecan. Dr. Sisti also has over 15 years experience as an Intellectual Property Attorney having worked for both law firms
and corporations such as Darby and Darby and Pfizer.

Director of Corporate Quality

Dr. Jay Sherbine

Jay has 30+ years of experience in R&D, compliance and commercial transfer activities for the manufacture of Active Pharmaceutical Ingredients and Drug Products. With over a dozen years in leading small molecule CMC teams at DuPont Pharma and Bristol Myers Squibb allocating resources across multiple sites and functions, Jay has been accountable for IND and NDA content and filings.

Jay has risen to leadership positions in organizations from 35 to 25,000 employees including concurrent Senior Leadership Team membership for Analytical Chemistry and Chemical Process R&D at Bristol Myers Squibb for a combined staff of 650.

Read More

As a Consultant, Jay has been assisting pharmaceutical companies enhance their Quality Management Systems and prepare for and manage regulatory agency inspections. An area of concentration has been qualification and validation including writing all aspects of these programs for a commercial manufacturing site. Additional focus has been on QC methods and instrumentation, including data integrity. Jay received his Ph.D. in Organic Chemistry from the University of Pittsburgh and his BA from Johns Hopkins University. He completed a post-doctoral program with SmithKline and French
Labs (later GSK) in Process Research and Development including transfer of a manufacturing process.


Dr. Pat N. Confalone

A graduate of M.I.T., Pat obtained a PhD at Harvard with Nobel laureate Prof. R.B. Woodward. After a post-doctoral stint, also with Prof. R.B. Woodward, directed toward the total synthesis of Vitamin B12, he joined the Chemical Research Department of Roche Pharmaceuticals.

Moving to DuPont, his Bioorganic Chemistry group developed the fluorescent dye-labeled reagents that were used in automated DNA sequencing, eventually employed in the human genome project. With DuPont’s Pharmaceutical Division, Pat’s Medicinal Chemistry department discovered CozaarTM, a major anti-hypertensive based on angiotensin II antagonism.

Read More

After 22 years in Discovery Research, he moved into pre-clinical development and his Chemical Process R&D organization carried out the chemical development of CozaarTM and SustivaTM, a highly successful therapeutic used to treat AIDS, currently in over five million patients.Together, these life-saving medicines generated cumulative sales of over $50 billion. As Vice President, Global R&D, DuPont Health, Nutrition, and Crop Protection, he led 300 scientists to build a world class pipeline of novel products, including RynaxypyrTM and CyazypyrTM, with world-wide sales over a billion dollars a year. He has presented more than 110 invited or plenary lectures worldwide, published more than 140 papers, obtained more than 50 U.S. Patents; he has been an associate editor of over ten peer-reviewed scientific journals. Pat has received numerous honors and awards, including the Harvard Graduate Society Prize, the Alpha Chi Sigma Award, the Robert A. Welch Lectureship, and the Philadelphia Organic Chemistry Award.

He was nominated to the Harvard Society of Fellows, is an elected Fellow of the American Association for the Advancement of Science, and served as Chairman of the Board of the American Chemical Society. Currently, Pat is an independent consultant to the biotechnology, pharmaceutical, and agrichemical industries.